Samuel Ponce-De-León-Rosales

Samuel Ponce-De-León-Rosales

Auto-generated profile, based on publicly available information

Samuel Ponce-De-León-Rosales

Facultad de Medicina, Universidad Nacional Autónoma de México, Ciudad de México, Mexico; Programa Universitario de Investigación sobre Riesgos Epidemiológicos y Emergentes, Universidad Nacional Autónoma de México, Ciudad de México, Mexico

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2019 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
RJRodrigo Jácome
Rodrigo Jácome
RCR. Carrasco-Hernández
R. Carrasco-Hernández
JCJosé Alberto Campillo-Balderas
José Alberto Campillo-Balderas
YLYolanda López-Vidal
Yolanda López-Vidal
ALAntonio Lazcano
Antonio Lazcano
SLSamuel Ponce de León
Samuel Ponce de León
Yellow fever virus historically was a frequent threat to American and European coasts. Medical milestones such as the discovery of mosquitoes as vectors and subsequently an effective vaccine significantly reduced its incidence, in spite of which, thousands of cases of this deathly disease still occur regularly in Sub-Saharan Africa and the Amazonian basin in South America, which are usually not reported. An urban outbreak in Angola, consecutive years of increasing incidence near major Brazilian cities, and imported cases in China, South America and Europe, have brought this virus back to the global spotlight. The aim of this article is to underline that the preventive YFV measures, such as vaccination, need to be carefully revised in order to minimize the risks of new YFV outbreaks, especially in urban or immunologically vulnerable places. Furthermore, this article highlights the diverse factors that have favored the spread of other Aedes spp.-associated arboviral diseases like Dengue, Chikungunya and Zika, to northern latitudes causing epidemics in the United States and Europe, emphasizing the possibility that YFV might follow the path of these viruses unless enhanced surveillance and efficient control systems are urgently initiated.

20 December 2019 in Salud Pública de México
Verified
Journal Article
Open access
PDF file
Guadalupe Miranda-NovalesGuadalupe Miranda-Novales
Guadalupe Miranda-Novales
KFKaren Flores-Moreno
Karen Flores-Moreno
YVYolanda López- Vidal
Yolanda López- Vidal
MRMauricio Rodríguez-Álvarez
Mauricio Rodríguez-Álvarez
FSFortino Solorzano Solórzano Santos
Fortino Solorzano Solórzano Santos
UNUncar Network
Uncar Network
Antimicrobial resistance and antibiotic consumption in Mexican hospitals

4 October 2022 in BMC Public Health
Verified
Journal Article
Open access
PDF file
NMNorma Piedad Mongua-Rodríguez
Norma Piedad Mongua-Rodríguez
MRMauricio Rodríguez
Mauricio Rodríguez
DZDaniela De la Rosa Zamboni
Daniela De la Rosa Zamboni
Maria-Eugenia Jimenez-CoronaMaria-Eugenia Jimenez-Corona
Maria-Eugenia Jimenez-Corona
MCMartha Lucía Castañeda-Cediel
Martha Lucía Castañeda-Cediel
LGLourdes García-García
Lourdes García-García
Background: Vaccination against COVID-19 is a primary tool for controlling the pandemic. However, the spread of vaccine hesitancy constitutes a significant threat to reverse progress in preventing the disease. Studies conducted in Mexico have revealed that vaccination intention in Mexico among the general population ranges from 62 to 82%. Objective: To know the prevalence of COVID-19 vaccine hesitancy and associated factors among academics, students, and administrative personnel of a public university in Mexico City. Methods: We administered an online survey investigating sociodemographic aspects, knowledge, attitudes, practices, and acceptance/hesitancy regarding the COVID-19 vaccine. Using generalized linear Poisson models, we analyzed factors associated with vaccine hesitancy, defined as not intending to be vaccinated within the following six months or refusing vaccination. Results: During May and June 2021, we studied 840 people, prevalence of vaccine hesitancy was 6%. Hesitancy was significantly associated with fear of adverse effects, distrust of physician’s recommendations, lack of knowledge regarding handwashing, age younger than 40 years, refusal to use face masks, and not having received influenza vaccination during the two previous seasons. Conclusions: Vaccine hesitancy in this population is low. Furthermore, our results allowed us the identification of characteristics that can improve vaccine promotion.

18 November 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Guadalupe Miranda-NovalesGuadalupe Miranda-Novales
Guadalupe Miranda-Novales
KFKaren Flores-Moreno
Karen Flores-Moreno
YVYolanda López- Vidal
Yolanda López- Vidal
SLSamuel Ponce de León-Rosales
Samuel Ponce de León-Rosales
PMPucra Network Members
Pucra Network Members
The rise in antimicrobial resistance (AMR) has complicated the management of urinary tract infections (UTIs). The objective of this study was to evaluate the antimicrobial susceptibility patterns of Escherichia coli and Klebsiella pneumoniae. Design: prospective observational study. Bacteria were classified as susceptible or resistant to ampicillin-sulbactam, amikacin, gentamicin, ciprofloxacin, norfloxacin, nitrofurantoin, trimethoprim-sulfamethoxazole (TMP/SMZ), ertapenem, meropenem, and fosfomycin. The sensitivity to fosfomycin and chloramphenicol was evaluated by the disk diffusion method. Statistical analysis: the chi-square test and Fisher’s exact test were used to compare differences between categories. A p value < 0.05 was considered statistically significant. Isolates were collected from January 2019 to November 2020 from 21 hospitals and laboratories. A total of 238 isolates were received: a total of 156 E. coli isolates and 82 K. pneumoniae isolates. The majority were community-acquired infections (64.1%). Resistance was >20% for beta-lactams, aminoglycosides, fluoroquinolones, and TMP/SMZ. For E. coli isolates, resistance was <20% for amikacin, fosfomycin, and nitrofurantoin; for K. pneumoniae, amikacin, fosfomycin, chloramphenicol, and norfloxacin. All were susceptible to carbapenems. K. pneumoniae isolates registered a higher proportion of extensively drug-resistant bacteria in comparison with E. coli (p = 0.0004). In total, multidrug-resistant bacteria represented 61% of all isolates. Isolates demonstrated high resistance to beta-lactams, fluoro-quinolones, and TMP/SMZ.

4 November 2015
Verified
Journal Article
Closed access
SLSamuel Ponce De León-Rosales
Samuel Ponce De León-Rosales
RARene Arredondo-Hernandez
Rene Arredondo-Hernandez
YVYolanda López- Vidal
Yolanda López- Vidal

30 March 2020 in medRxiv
Verified
Preprint
Open access
PDF file
GCGustavo Cruz-Pacheco
Gustavo Cruz-Pacheco
JBJ.F Bustamante-Castañeda
J.F Bustamante-Castañeda
Jean-Guy CaputoJean-Guy Caputo
Jean-Guy Caputo
Maria-Eugenia Jimenez-CoronaMaria-Eugenia Jimenez-Corona
Maria-Eugenia Jimenez-Corona
SPSamuel Ponce-De-Leon
Samuel Ponce-De-Leon
Summary: On January 23, 2020, China imposed a quarantine on the city of Wuhan to contain the SARS-CoV-2 outbreak. Regardless of this measure the new infection has spread to several countries around the world. Here, we developed a method to study the dissemination of this infection by the airline routes and we give estimations of the time of arrival of the outbreaks to the different cities. In this work we show an analysis of the dispersion of this infection to other cities by airlines based on the classic model the Kermack and McKendrick complemented with diffusion on a graph composed of nodes which represent the cities and edges which represent the airline routes. We do several numerical simulations to estimate the date of arrival to different cities starting the infection at Wuhan, China and to show the robustness of the estimation respect to changes in the epidemiological parameters and to changes on the graph. we use Mexico City as an example. In this case, our estimate of the arrival time is between March 20 and March 30, 2020. This analysis is limited to the analysis of dispersion by airlines, so this estimate should be taken as an overestimate since the infection can arrive by other means. This model estimates the arrival of the infectious outbreak to Mexico between March 20 and March 30. This estimation gives a time period to implement and strengthen preventive measures aimed at the general population, as well as to strengthen hospital infrastructure and training of human resources in health.